[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100561763":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":164,"collaborators":25,"id":166,"slug":167,"hasResults":168,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":168,"sex":174,"minAge":175,"maxAge":25,"enrollmentInfo":176,"targetDuration":25,"studyType":179,"phases":180,"briefSummary":182,"conditions":183,"keywords":187,"overallStatus":38,"whyStopped":25,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":199},{"fullName":5,"class":6},"Xinnate AB","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TCP-25","EXPERIMENTAL","Topical gel",[13],"Drug: TCP-25 gel",{"label":15,"type":16,"description":17,"interventionNames":18},"Vehicle","PLACEBO_COMPARATOR","Placebo gel",[19],"Drug: Vehicle (placebo)",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","TCP-25 gel",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Vehicle (placebo)",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Head of Clinical Development","CONTACT","46462756000","info@xinnate.com",[36,54,68,78,89,102,116,125,133,152],{"facility":37,"status":38,"city":39,"state":40,"zip":41,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Cincinnati Children's Hospital Medical Center","RECRUITING","Cincinnati","Ohio","45229","United States","US",{"type":45,"coordinates":46},"Point",[47,48],-84.51439,39.12711,{"lat":48,"lon":47},[51],{"name":52,"role":32,"phone":25,"phoneExt":25,"email":53},"Dr. Kalyani Marathe, PI, MD","kalyani.marathe@cchmc.org",{"facility":55,"status":38,"city":56,"state":25,"zip":25,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":63,"contacts":64},"Hopital St Louis","Paris","France","FR",{"type":45,"coordinates":60},[61,62],2.3488,48.85341,{"lat":62,"lon":61},[65],{"name":66,"role":67,"phone":25,"phoneExt":25,"email":25},"Dr BATAILLE, MD","PRINCIPAL_INVESTIGATOR",{"facility":69,"status":38,"city":70,"state":25,"zip":25,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":77,"contacts":25},"Andreas Syngros Hospital of Veneral & Dermatological Diseases","Athens","Greece","GR",{"type":45,"coordinates":74},[75,76],23.72784,37.98376,{"lat":76,"lon":75},{"facility":79,"status":38,"city":80,"state":25,"zip":25,"country":71,"countryCode":72,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Hospital Of Skin And Venereal Diseases of Thessaloniki","Thessaloniki",{"type":45,"coordinates":82},[83,84],22.93493,40.64072,{"lat":84,"lon":83},[87],{"name":88,"role":67,"phone":25,"phoneExt":25,"email":25},"Dimitra Kiritisi",{"facility":90,"status":38,"city":91,"state":25,"zip":25,"country":92,"countryCode":93,"cosmosGeoPoint":94,"geoPoint":98,"contacts":99},"IDI Istituto Dermopatico dell'Immacolata IRCCS","Rome","Italy","IT",{"type":45,"coordinates":95},[96,97],12.51133,41.89193,{"lat":97,"lon":96},[100],{"name":101,"role":67,"phone":25,"phoneExt":25,"email":25},"Dr. Didona, MD",{"facility":103,"status":38,"city":104,"state":105,"zip":25,"country":106,"countryCode":107,"cosmosGeoPoint":108,"geoPoint":112,"contacts":113},"San Joan de Deu, SJD Children's hospital Barcelona","Barcelona","Catalonia","Spain","ES",{"type":45,"coordinates":109},[110,111],2.15899,41.38879,{"lat":111,"lon":110},[114],{"name":115,"role":67,"phone":25,"phoneExt":25,"email":25},"Vicente Villa, MD",{"facility":117,"status":38,"city":104,"state":25,"zip":25,"country":106,"countryCode":107,"cosmosGeoPoint":118,"geoPoint":120,"contacts":121},"Hospital Clinic de Barcelona",{"type":45,"coordinates":119},[110,111],{"lat":111,"lon":110},[122],{"name":123,"role":32,"phone":25,"phoneExt":25,"email":124},"Riera Monroig, MD","JRIERA@clinic.cat",{"facility":126,"status":38,"city":127,"state":25,"zip":25,"country":106,"countryCode":107,"cosmosGeoPoint":128,"geoPoint":132,"contacts":25},"Hospital Univ La Paz","Madrid",{"type":45,"coordinates":129},[130,131],-3.70256,40.4165,{"lat":131,"lon":130},{"facility":134,"status":38,"city":135,"state":136,"zip":137,"country":138,"countryCode":139,"cosmosGeoPoint":140,"geoPoint":144,"contacts":145},"University hospital","Lund","Skåne County","23735","Sweden","SE",{"type":45,"coordinates":141},[142,143],13.19321,55.70584,{"lat":143,"lon":142},[146,150],{"name":147,"role":32,"phone":148,"phoneExt":25,"email":149},"Emma Belfrage Sub-investigator","46 46 17 100","info@regionskane.se",{"name":25,"role":32,"phone":25,"phoneExt":25,"email":151},"emmga.belfrage@skane.se",{"facility":153,"status":38,"city":154,"state":25,"zip":25,"country":138,"countryCode":139,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Akademiska sjukhuset","Uppsala",{"type":45,"coordinates":156},[157,158],17.63889,59.85882,{"lat":158,"lon":157},[161],{"name":162,"role":163,"phone":25,"phoneExt":25,"email":25},"Katja Holmgren, MD","SUB_INVESTIGATOR",{"type":165,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100561763","phase-2-a-phase-2-study-of-tcp-25-gel-in-patients-with-epidermolysis-bullosa-step-study-100561763",false,"NCT06594393","A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-study","A Randomized, Double-blind, Vehicle-controlled Phase 2 Study to Evaluate Efficacy, Safety, and Tolerability of Topically Applied TCP-25 in Patients With Epidermolysis Bullosa","STEP","Inclusion Criteria:\n\n* Male or female patients with documented diagnosis of DEB or JEB, confirmed by genetic testing and\u002For by a skin biopsy with immunofluorescence mapping.\n* Patients ≥4 years old. Note: Initially, patients ≥12 years will be enrolled. Enrollment will be open to 4 to 11 year old pediatric patients (both inclusive), after a DMC reviews and provides a positive opinion regarding the safety and tolerability of the IMP in at least 3 patients 12 to 18 years old who have completed at least 4 weeks of IMP use.\n\nExclusion Criteria:\n\n* The patient has any subtype of EB other than DEB or JEB.\n* The patient is currently being treated or planned to be treated with systemic antibiotics.\n\nNote: Use of preventive and\u002For anti-inflammatory antibiotic treatment, including doxycycline, on an established treatment regimen (stable dose for ≥6 weeks before the Baseline Visit) is permitted. Use of topical antibiotics on the index wounds within 7 days before the Baseline Visit is prohibited.\n\n• Use of systemic corticosteroids \\>0.2 mg\u002Fkg prednisone dose equivalent per day within 30 days or use of topical corticosteroids on index wounds within 7 days before the Screening Visit.\n\nNote: Corticosteroids for inhalation, ophthalmic, or intranasal use are permitted.\n\n• The patient has a history of or current malignancy over the index wound, eg, basal cell carcinoma or squamous cell carcinoma.","ALL","4 Years",{"count":177,"type":178},32,"ESTIMATED","INTERVENTIONAL",[181],"PHASE2","This is a Phase 2, double-blind, randomized, vehicle-controlled study designed to evaluate efficacy, safety, and tolerability of topically applied TCP-25 gel in patients with confirmed DEB or JEB. The study will implement intrasubject randomization, ie, a pair of matching index wounds will be randomly assigned to be treated with a local application of either TCP 25 gel or vehicle gel.",[184,185,186],"Epidermolysis Bullosa (EB)","Dystrophic Epidermolysis Bullosa","Junctional Epidermolysis Bullosa",[188,189],"epidermolysis bullosa","topical treatment","2026-08-11",{"date":192,"type":193},"2026-08-12","ACTUAL",{"date":195,"type":193},"2026-01-30",{"date":197,"type":178},"2027-06-30",{"name":5,"class":6},10]